These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Influence of short-term dexamethasone on the efficacy of Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729 [TBL] [Abstract][Full Text] [Related]
43. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056 [TBL] [Abstract][Full Text] [Related]
44. Preclinical investigations using [ Tschan VJ; Borgna F; Busslinger SD; Stirn M; Rodriguez JMM; Bernhardt P; Schibli R; Müller C Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3639-3650. PubMed ID: 35635566 [TBL] [Abstract][Full Text] [Related]
45. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID; BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution. Śmiłowicz D; Schlyer D; Boros E; Meimetis L Mol Pharm; 2022 Sep; 19(9):3217-3227. PubMed ID: 35895995 [TBL] [Abstract][Full Text] [Related]
53. Dosimetry and safety of Paganelli G; Sarnelli A; Severi S; Sansovini M; Belli ML; Monti M; Foca F; Celli M; Nicolini S; Tardelli E; Marini I; Matteucci F; Giganti M; Di Iorio V; De Giorgi U Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3008-3017. PubMed ID: 32430583 [TBL] [Abstract][Full Text] [Related]
54. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278 [TBL] [Abstract][Full Text] [Related]
55. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients. Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032 [TBL] [Abstract][Full Text] [Related]
56. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
57. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [ Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A Eur Urol Oncol; 2022 Oct; 5(5):530-536. PubMed ID: 35697600 [TBL] [Abstract][Full Text] [Related]
58. Prediction of response and survival after standardized treatment with 7400 MBq Rasul S; Hartenbach M; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat S; Wadsak W; Mitterhauser M; Pichler V; Vraka C; Hacker M; Haug AR Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1650-1657. PubMed ID: 33128131 [TBL] [Abstract][Full Text] [Related]
59. Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086 [TBL] [Abstract][Full Text] [Related]